FibroGen, Inc. — FY2020 Form 10-K
Reporting period: Year ended December 31, 2020. The filing identifies FibroGen, Inc. (Nasdaq: FGEN) as the registrant; the request’s company name, Kyntra Bio, Inc., does not match the filing.
Business context and reporting period
FibroGen is a biopharmaceutical company developing therapies for anemia, fibrosis, and cancer. Roxadustat is approved for CKD anemia in China, Japan, and Chile; pamrevlumab remains in Phase 3 development for idiopathic pulmonary fibrosis (IPF), locally advanced pancreatic cancer, and Duchenne muscular dystrophy (DMD). Revenue comes primarily from roxadustat collaborations with Astellas and AstraZeneca and commercial sales in China.
Financial and operating highlights
| Metric | FY2020 | FY2019 |
|---|---|---|
| Total revenue | $176.3 million | $256.6 million |
| Operating costs and expenses | $368.2 million | $345.9 million |
| Operating loss | $191.9 million | $89.3 million |
| Net loss | $189.3 million | $77.0 million |
| Net loss per share, basic and diluted | $2.11 | $0.89 |
| Research and development expense | $252.9 million | $209.3 million |
| Cash and cash equivalents | $678.4 million | $126.3 million |
| Short- and long-term investments | $8.4 million | $468.6 million |
| Accounts receivable | $41.9 million | $28.5 million |
- Revenue declined 31%, largely reflecting fewer large collaboration milestone revenues than in 2019. FY2020 included $72.5 million of net China roxadustat sales, $80.6 million of development revenue, $14.3 million of license revenue, and $8.9 million of drug-product revenue.
- China roxadustat commercial sales represented 42% of revenue; collaboration-related revenue represented 58%. China net sales rose from $1.7 million in 2019, when launch had only recently begun.
- Operating expenses increased 6%. R&D rose 21%, mainly due to pamrevlumab Phase 3 trials and China post-approval safety studies. SG&A declined 21%, including an $84.4 million reversal of previously accrued China co-promotion expenses following a collaboration amendment.
- The cash flow statement reports $81.6 million of cash provided by operating activities in 2020, compared with $78.7 million used in 2019. Investing activities provided $452.5 million, primarily reflecting maturities and sales of investments. Cash and cash equivalents increased $552.1 million during the year.
- The filing reports no conventional borrowings in the provided financial statements. Finance lease liabilities were $37.7 million at year-end, and product development obligations were $18.7 million, principally Finnish TEKES loans. Total liabilities were $385.4 million; current assets were $755.1 million and current liabilities $163.2 million.
Material changes versus the prior period
- Net loss more than doubled, primarily due to lower revenue and higher operating expenses. Revenue was down $80.3 million, including a sharp reduction in milestone-related license revenue after substantial milestones were recognized in 2019.
- China net product revenue grew to $72.5 million. The company reported roxadustat listings at hospitals representing approximately 70% of the China CKD-anemia market opportunity at year-end.
- The July 2020 China collaboration amendment changed distribution and co-promotion arrangements. It reduced historical accrued co-promotion expenses by $84.4 million and established a jointly owned distribution entity with AstraZeneca, which began operations in January 2021.
- Cash and cash equivalents increased substantially as investment holdings were converted largely to cash; short- and long-term investments fell from $468.6 million to $8.4 million.
Outlook, commentary, and risks
- Roxadustat in the U.S.: The FDA requested additional analyses and extended its review. On March 1, 2021, it announced an advisory committee review; FibroGen said no decision would be received by the March 20, 2021 PDUFA goal date. The impact on approval and labeling was uncertain.
- Other expected milestones: Astellas expected an EU decision around mid-2021. FibroGen expected CIA Phase 2 topline data in the second half of 2021, MDS Phase 3 topline data in the first half of 2022, and key pamrevlumab Phase 3 data in the second half of 2022.
- Management expected continued annual losses and substantial spending on clinical development, manufacturing, regulatory work, and commercialization. It believed available resources would fund anticipated requirements for at least 12 months from the filing, while noting that assumptions could change and additional financing might be needed.
- COVID-19 had slowed clinical-trial enrollment, particularly in IPF; further delays, supply interruptions, and operational effects remained possible. Other key risks include clinical and regulatory uncertainty, roxadustat cardiovascular safety and potential label limitations, dependence on Astellas and AstraZeneca, reimbursement and pricing pressures, manufacturing concentration, and China-related operating and regulatory risks.
- Controls and audit: The auditor gave an unqualified opinion on the financial statements but concluded internal control over financial reporting was ineffective due to material weaknesses in risk assessment and controls over drug-product shipments and variable-consideration estimates. The weaknesses did not cause a material financial-statement misstatement, but did result in immaterial out-of-period adjustments.
- FibroGen appealed a UK patent ruling that invalidated certain UK designations of its HIF-related patents. The filing reported no material legal accrual because the outcome and exposure could not be reasonably estimated.
Important facts for investors to verify
- Subsequent FDA advisory committee timing, review outcome, safety assessment, and any resulting roxadustat approval or label restrictions.
- China roxadustat sales, hospital access, reimbursement and price renegotiation, and the financial effect of the revised AstraZeneca distribution and profit-sharing structure.
- Cash burn and runway as clinical-trial spending grows; reconcile operating cash flow with milestone receipts, working-capital movements, and reported losses.
- Progress and results of the stated 2021–2022 clinical and regulatory milestones, including the effects of COVID-19 enrollment delays.
- Remediation and independent testing of the material weaknesses in financial reporting controls, especially revenue shipment and variable-consideration controls.